NCT00389857View on ClinicalTrials.gov

Trial to Collect Safety Data and Sera for Immunogenicity Testing

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

July 31, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Virus Vaccine (Fluzone®)

0.25 mL, Intramuscular (infant/children dose)

BIOLOGICAL

Influenza Virus Vaccine (Fluzone®)

0.25 mL, Intramuscular (infant/children dose)

Trial Locations (1)

23510

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00389857 - Trial to Collect Safety Data and Sera for Immunogenicity Testing | Biotech Hunter | Biotech Hunter